IP Library Granted Patent US 9,751,908
Granted Patent B2
US 9,751,908 · App. 14/774,843 · Granted Sep 5, 2017

Convergent processes for preparing macrolide antibacterial agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,751,908
App. No.
14/774,843
Granted
Sep 5, 2017
Kind
B2
Abstract

The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.

Claims (65)

1. A process for preparing a compound of formula (I)

or a pharmaceutically acceptable salt thereof; wherein

R 1 is a desosamine or a desosamine derivative;

A is —CH 2 —, —C(O)—, —C(O)O—, —C(O)NH—, —S(O) 2 —, —S(O) 2 NH—, or —C(O)NHS(O) 2 —;

B is saturated C 0 -C 10 ; or B is unsaturated C 2 -C 10 ; or -A-B- taken together is alkylene, alkenylene, cycloalkylene, or arylene;

C represents 2 substituents independently selected in each instance from the group consisting of hydrogen, halogen, hydroxy, acyl, acyloxy, sulfonyl, ureyl, and carbamoyl, and alkyl, alkoxy, heteroalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl, each of which is optionally substituted; and

W is hydrogen, F, Cl, Br, I, or OH;

the process comprising (A) contacting a compound of formula

or a salt thereof, where R 100 is a hydroxyl protecting group, and L is a leaving group, with a compound of formula

or a salt thereof, where C is as defined herein, and C P is a protected form of C, and a base, to prepare a compound of formula

or a salt thereof; or

(C) contacting a compound of formula

or a salt thereof, with an acid to prepare a compound of formula

or a salt thereof; or

(E) contacting a compound of formula

or a salt thereof, with an oxidizing agent to prepare a compound of formula

or a salt thereof; or

(F) contacting a compound of formula

or a salt thereof, with a hydroxylating or halogenating agent to prepare a compound of formula

or a salt thereof, wherein W is F, Cl, Br, I, or OH;

any combination of the foregoing.

2. The process of claim 1 comprising

(a) contacting a compound of formula

or a salt thereof, where R 100 is a hydroxyl protecting group, and L is a leaving group, with a compound of formula

or a salt thereof, where N P is a protected amine, and a base; to prepare a compound of formula

or a salt thereof; or

(c) contacting a compound of formula

or a salt thereof, with an acid to prepare a compound of formula

or a salt thereof; or

(e) contacting a compound of formula

or a salt thereof, with an oxidizing agent to prepare a compound of formula

or a salt thereof; or

(g) contacting a compound of formula

or a salt thereof, with a fluorinating agent to prepare a compound of formula

or a salt thereof; or

any combination of the foregoing.

3. The process of claim 2 wherein N P is NHC(O)CF 3 .

4. The process of claim 1 comprising

(a′) contacting a compound of formula

or a salt thereof, where R 100 is a hydroxyl protecting group, and L is a leaving group, with a compound of formula

or a salt thereof, and a base; to prepare a compound of formula

or a salt thereof; or

(b′) contacting a compound of formula

or a salt thereof, with an acid to prepare a compound of formula

or a salt thereof; or

(c′) contacting a compound of formula

or a salt thereof, with an oxidizing agent to prepare a compound of formula

or a salt thereof; or

(d′) contacting a compound of formula

or a salt thereof, with a fluorinating agent to prepare a compound of formula

or a salt thereof; or

any combination of the foregoing.

5. The process of claim 1 wherein the leaving group is halo, pentafluorophenoxy, a sulfonate, a hydroxyamino, or imidazol-1-yl.

6. The process of claim 1 wherein the base is DBU.

7. The process of claim 1 wherein the halogenating agent is NFSI, F-TEDA, or 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate).

8. The process of claim 1 wherein C is aryl, heteroaryl, arylalkyl, or heteroarylalkyl, each of which is optionally substituted.

9. The process of claim 1 wherein A is CH 2 .

10. The process of claim 1 wherein B is (CH 2 ) n and n is an integer from 2 to 6.

11. The process of claim 1 wherein B is (CH 2 ) n , and n is 2, 3, or 4.

12. The process of claim 1 wherein B is (CH 2 ) n , and n is 3.

13. The process of claim 1 wherein R 100 is acyl.

14. The process of claim 1 wherein R 100 is alkylcarbonyl or optionally substituted benzoyl.

15. The process of claim 1 wherein R 100 is acetyl or benzoyl.

16. The process of claim 1 wherein W is H or F.

17. The process of claim 1 wherein W is F.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: CEMPRA PHARMACEUTICALS, INC.
To: TETARD, INC.
Reel/Frame 050056/0731 →
RELEASE OF SECURITY INTEREST Recorded Jun 4, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC
To: CEMPRA PHARMACEUTICALS, INC.
Reel/Frame 049363/0706 →
SECURITY INTEREST Recorded Jan 8, 2018
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; CEM-102 PHARMACEUTICALS, INC.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 045019/0552 →